AIM: Diabetes is associated with abnormalities in lipid profile and increased oxidative stress. Statins are preferred agents in diabetic patients due to their antioxidant and LDL-C lowering effects. This study is designed to compare the effects of atorvastatin and rosuvastatin on low density lipoprotein cholesterol (LDL-C), lipid hydroperoxide (LOOH), total oxidant status (TOS) and total antioxidant capacity (TAC) in diabetic patients with hyperlipidemia. MATERIALS AND METHODS: Sixty two patients who have type 2 diabetes mellitus with serum LDL levels more than 100mg/dL were randomly assigned to receive atorvastatin 20mg (n=31) or rosuvastatin 10mg (n=31). Blood tests were performed at the beginning of the study and after three months. RESULTS: There were no statistically significant differences in the pre- and after treatment levels of the LDL-C between groups. TAC values were increased in both groups and statistically significant in the former group (p=0.007). There was no difference between the change percentages ((after treatment TAC-pretreatment TAC)/pretreatment level) of TAC between two treatment groups. The effects of two drugs on the other oxidative parameters were not significantly different. CONCLUSION: Both atorvastatin and rosuvastatin may be helpful in reducing increased oxidative stress in diabetic patients with hyperlipidemia.
RCT Entities:
AIM: Diabetes is associated with abnormalities in lipid profile and increased oxidative stress. Statins are preferred agents in diabeticpatients due to their antioxidant and LDL-C lowering effects. This study is designed to compare the effects of atorvastatin and rosuvastatin on low density lipoprotein cholesterol (LDL-C), lipid hydroperoxide (LOOH), total oxidant status (TOS) and total antioxidant capacity (TAC) in diabeticpatients with hyperlipidemia. MATERIALS AND METHODS: Sixty two patients who have type 2 diabetes mellitus with serum LDL levels more than 100mg/dL were randomly assigned to receive atorvastatin 20mg (n=31) or rosuvastatin 10mg (n=31). Blood tests were performed at the beginning of the study and after three months. RESULTS: There were no statistically significant differences in the pre- and after treatment levels of the LDL-C between groups. TAC values were increased in both groups and statistically significant in the former group (p=0.007). There was no difference between the change percentages ((after treatment TAC-pretreatment TAC)/pretreatment level) of TAC between two treatment groups. The effects of two drugs on the other oxidative parameters were not significantly different. CONCLUSION: Both atorvastatin and rosuvastatin may be helpful in reducing increased oxidative stress in diabeticpatients with hyperlipidemia.
Authors: Geannyne Villegas-Rivera; Luis Miguel Román-Pintos; Ernesto Germán Cardona-Muñoz; Oscar Arias-Carvajal; Adolfo Daniel Rodríguez-Carrizalez; Rogelio Troyo-Sanromán; Fermín Paul Pacheco-Moisés; Aldo Moreno-Ulloa; Alejandra Guillermina Miranda-Díaz Journal: Oxid Med Cell Longev Date: 2015-07-28 Impact factor: 6.543
Authors: Luis Miguel Román-Pintos; Geannyne Villegas-Rivera; Adolfo Daniel Rodríguez-Carrizalez; Alejandra Guillermina Miranda-Díaz; Ernesto Germán Cardona-Muñoz Journal: J Diabetes Res Date: 2016-12-12 Impact factor: 4.011